IO Biotech
IOBT
IOBT was delisted on the 6th of April, 2026.
15 hedge funds and large institutions have $24M invested in IO Biotech in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 5 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
5.8% less ownership
Funds ownership: 48.29% → 42.49% (-5.8%)
8% less capital invested
Capital invested by funds: $26.1M → $24M (-$2.13M)
12% less funds holding
Funds holding: 17 → 15 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$205K |
| 2 |
AAM
Aureus Asset Management
Boston,
Massachusetts
|
+$85.5K |
| 3 |
STA
Summit Trail Advisors
New York
|
+$85.5K |
| 4 |
Morgan Stanley
New York
|
+$50.3K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$25.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.63M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$783K |
| 3 |
NM
Newtyn Management
New York
|
-$92.3K |
| 4 |
Millennium Management
New York
|
-$37K |
| 5 |
CC
Cannell Capital
Alta,
Wyoming
|
-$23.6K |
IOBT Hedge Fund Activity: Q2 2023 in Review
15 of the 6,373 institutional investors tracked by Wall St. Rank reported a position in IO Biotech (IOBT) for Q2 2023, worth a combined $24M — down 8.2% from $26.1M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of IOBT and 3 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 3 added.
The largest buyer was PFM Health Sciences, adding an estimated $205K. The largest seller was Point72 Asset Management, exiting entirely with an estimated $2.63M sold.
- 15 institutional investors held IO Biotech (IOBT) as of Q2 2023, down from 17 in Q1 2023.
- Funds reported $24M of IO Biotech stock for Q2 2023, down 8.2% quarter-over-quarter.
- 3 funds opened new IO Biotech positions in Q2 2023 and 5 closed out, a net change of -2 holders.
- The largest IO Biotech buyer in Q2 2023 was PFM Health Sciences, an estimated $205K added.
- The largest IO Biotech seller in Q2 2023 was Point72 Asset Management, an estimated $2.63M sold.
Based on aggregated 13F filings for Q2 2023.